{
    "clinical_study": {
        "@rank": "1438", 
        "acronym": "NOBLE", 
        "arm_group": {
            "arm_group_label": "Norspan patch (Buprenorphine)", 
            "arm_group_type": "Other", 
            "description": "Trade name is Norspan. Buprenorphine 5\u03bcg/h, 10 \u03bcg/h, 20 \u03bcg/h patches will be used (4 patches a box). Patch will be administered every 7th day."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the pain reduction rate after 8 weeks treatment of\n      NORSPAN\u00ae from baseline.\n\n      And secondary purpose are: pain reduction rate after 4 weeks treatment from baseline(week 0)\n      the EQ-5D, the pain and sleep questionnaire, physician's overall satisfaction subject's\n      overall satisfaction, and safety"
        }, 
        "brief_title": "An Interventional Study to Assess the Efficacy and Safety of Buprenorphine in Korean Patients With Spinal Disorders", 
        "completion_date": {
            "#text": "October 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Spinal Disorder", 
        "condition_browse": {
            "mesh_term": "Spinal Diseases"
        }, 
        "detailed_description": {
            "textblock": "Upon providing written informed consent, subject will be screened in the study and\n      assessment will be performed at that time such as safety laboratory assessments, physical\n      examination, vital sign, medical history taking, 24 hours pain intensity score, EQ-5D, pain\n      and sleep questionnaire, physician's overall satisfaction and subject's overall\n      satisfaction.\n\n      If patient is eligible in inclusion/exclusion criteria at the time of visit 1, the patient\n      will receive treatment with NORSPAN\u00ae.\n\n      Treatment with NORSPAN\u00ae  will be started from 5 \u03bcg/h (1 patch a week) for 2 weeks, and\n      proper titration (up-titration) will be allowed at visit 2(wk 2) and at visit 3(wk 4)\n      according to the investigator's decision."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  20 years old or above male or female Korean patients\n\n          -  Patients who have spinal disorders related pain\n\n          -  Patients who had been treated with weak opioids and/or NSAIDs before study\n             participation\n\n          -  Patients who have moderate to severe pain intensity\n\n          -  Na\u00efve patients for Buprenorphine (Na\u00efve patient are defined as those who had not been\n             treated with Buprenophine for 90 days)\n\n          -  Patients who signed a written informed consent form\n\n        Exclusion Criteria:\n\n          -  Women of child-bearing potential, defined as all women physiologically capable of\n             becoming pregnant. UNLESS they are:\n\n               -  women whose partners have been sterilized by vasectomy or other means\n\n               -  using two birth control methods. The two methods can be a double barrier method\n                  or a barrier method plus a hormonal method. Adequate barrier methods of\n                  contraception include: diaphragm, condom (by the partner), intrauterine device\n                  (copper or hormonal), sponge or spermicide. Hormonal contraceptives include any\n                  marketed contraceptive agent that includes an estrogen and/or a progestational\n                  agent.\n\n          -  Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a\n             female after conception and until the termination of gestation, confirmed by a\n             positive urine pregnancy test\n\n          -  Patients with known hypersensitivity to buprenorphine or to any of the excipients\n\n          -  Patients with severely impaired respiratory function or respiratory depression status\n\n          -  Patients concurrently receiving MAOIs or who have received MAOIs within the previous\n             two weeks\n\n          -  Patients with convulsive disorders, head injury, shock, a reduced level of\n             consciousness of uncertain origin, intracranial lesions or increased intracranial\n             pressure, or in patients with severe hepatic impairment\n\n          -  Patients with biliary tract disorders\n\n          -  Patients known to have, or suspected of having a history of drug abuse\n\n          -  Patients with history of opioid or drug dependence\n\n          -  Patients who are concurrently taking other CNS depressants or muscle relaxants that\n             may cause respiratory depression, hypotension, profound sedation or potentially\n             result in coma.\n\n          -  Patients who are taking Buprenorphine or strong opioid.\n\n          -  Any situation where Buprenorphine is contraindicated\n\n          -  Major surgery within 1 month prior to screening or planned surgery Mainly pain\n             originated other than spinal disorders disease\n\n          -  Non-malignant patients or cancer patients who are receiving any oncology treatment\n             that could affect the measure of pain control\n\n          -  With a disability that may prevent the patient from completing all study requirements\n             and in particular, interfere with 24hrs pain intensity score\n\n          -  Clinically significant impairment of cardiovascular, respiratory and renal function\n\n          -  Patient who needs acute dose titration or whose pain intensity fluctuate\n             significantly in a short period according to investigator's judgment\n\n          -  Having used other investigational drugs at the time of enrollment, or within 30 days\n             of enrollment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "242", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 18, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01818700", 
            "org_study_id": "BUP12-KR-401"
        }, 
        "intervention": {
            "arm_group_label": "Norspan patch (Buprenorphine)", 
            "description": "8weeks treatment with Norspan\u00ae(Buprenorphine)", 
            "intervention_name": "Buprenorphine", 
            "intervention_type": "Drug", 
            "other_name": "Buprenorphine"
        }, 
        "intervention_browse": {
            "mesh_term": "Buprenorphine"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "August 5, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Daegu", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "YeungNam University Medical center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Daejeon", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Chungnam National University Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gwangju", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Chonnam National University hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pusan", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Pusan National University Yangsan Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Severance Hospital, Yonsei University Health System"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Samsung Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Gangnam Severance Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Hanyang University Seoul Hospital"
                }
            }
        ], 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Multicenter, Phase IV, Interventional Study to Assess the Efficacy and Safety of NORSPAN\u00ae (Buprenorphine) in Korean Patients With Spinal Disorders (NOBLE)", 
        "other_outcome": {
            "description": "Physician and subject should choose the most best description of the satisfaction seven statement.", 
            "measure": "Overall satisfaction of physician and subject", 
            "safety_issue": "No", 
            "time_frame": "8 weeks"
        }, 
        "overall_official": {
            "affiliation": "Samsung Medical Center", 
            "last_name": "Whan Eoh", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "South Korea: Korea Food and Drug Administration (KFDA)", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The primary efficacy outcome is the actual reduction rate of pain intensity (0 -10, VAS) score within 8 weeks.", 
            "measure": "Pain intensity (0 -10, VAS) score-NRS(Numeric Rating Scale)", 
            "safety_issue": "No", 
            "time_frame": "8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01818700"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "5 Dimension\n: Subject should choose the most best description of the three statement per each question.\nAnd last question is 'Your own health state today'.", 
            "measure": "EQ-5D-EuroQOL-5 Dimension", 
            "safety_issue": "No", 
            "time_frame": "8 weeks"
        }, 
        "source": "Mundipharma Pte Ltd.", 
        "sponsors": {
            "collaborator": {
                "agency": "Dream CIS", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Mundipharma Pte Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}